VIVE
Viveve Medical, Inc.
0.00
-
0.00
33.33%
8 x 0.00
10 x 0.00
bid
ask
02:20 PM
Bearish
16
Bullish
55
sentiment
0.00
day range
0.00
0.00
52 week range
0.06
Prev Close0.00
Open0.00
Low0.00
High0.00
Volume11.53K
Avg. Volume2.95K
Market Cap2.14K
Inst. Own4.74%
Beta0.16
Short Ratio4.15
Div & Yield0.00 /
EPS-2.65
P/E0.00
1yr Target3.10
50day MA0.33
200day MA0.60
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-01-04 | 2023-09 | 0 | N/A | N/A | N/A |
2023-10-05 | 2023-06 | 0 | N/A | N/A | N/A |
2023-07-06 | 2023-03 | 0 | N/A | N/A | N/A |
2023-04-06 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-10 | 2022-09 | 0 | -0.59 | N/A | N/A |
2022-08-11 | 2022-06 | 0 | -0.67 | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2020-11-25 | Ladenburg Thalmann | Upgrade | Neutral | Buy |
2020-11-25 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
2020-11-25 | Maxim Group | Downgrade | Buy | Hold |
2020-11-25 | Mizuho | Downgrade | Buy | Underperform |
2020-11-25 | Mizuho Securities | Downgrade | Buy | Underperform |
2020-11-25 | Stifel Nicolaus | Downgrade | Buy | Hold |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-01-28 | ATKINSON JAMES G | President | 964.61K | Stock Award(Grant) |
2019-03-31 | BASTA STEVEN L | Director | 24.20K | Stock Award(Grant) |
2018-07-01 | BUSH LORI H | Director | 6.53K | Stock Award(Grant) |
2019-01-28 | DURBIN SCOTT C | Chief Executive Officer | 73.82K | Stock Award(Grant) |
2019-09-30 | GOLDMAN SACHS GROUP INC. | Unknown | 0.00 | Sale |
2018-12-30 | JANNEY DANIEL SPENCER | Director | 1.44M | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | Blackrock Inc. | 244.23K | 23.93K | 2.28% |
2022-12-30 | Vanguard Group, Inc. (The) | 60.34K | 5.91K | 0.56% |
2022-12-30 | State Street Corporation | 55.37K | 5.43K | 0.52% |
2022-12-30 | Geode Capital Management, LLC | 51.36K | 5.03K | 0.48% |
2022-12-30 | Renaissance Technologies, LLC | 32.00K | 3.14K | 0.30% |
2022-12-30 | Northern Trust Corporation | 17.07K | 1.67K | 0.16% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Extended Market Index Fund | 114.01K | 11.17K | 1.06% |
2022-11-29 | Fidelity Extended Market Index Fund | 41.62K | 4.08K | 0.39% |
2022-11-29 | Fidelity Series Total Market Index Fund | 5.48K | 537.00 | 0.05% |
2022-11-29 | Fidelity NASDAQ Composite Index Fund | 3.78K | 370.00 | 0.04% |
Split
...
Split | Date |
---|---|
1 : 10 | 2020-12-02 |
1 : 100 | 2019-09-19 |
1 : 8 | 2016-04-18 |
1 : 100 | 2014-09-25 |
This topic has been deleted. Only users with topic management privileges can see it.
-
It will gap up to. 45 at open
-
FDA approval and distribution agreement with a co in middle east . Strong buy recommendation from analyst . We will see $2 this week ???
-
This is going to rip AH
-
Added 5k at .41 . Thanks you penny flippers
-
It’s unable to break .42
-
I don’t really understand the market anymore. Possible manipulation ?
-
Penny flippers are the ones drawing this down . We will see at market open
-
Stop selling guys . Let her run
-
PR IS OUT
-
Did they release the FDA approval PR?
-
FDA approval PR anytime
-
Why the sudden drop?
-
-
Seeing some big buys
-
Nothing from conf ?
-
-
Volume incoming
-
Anyone called the company about the news ?
-
Need PR for volume
-
Why Is Viveve Medical (VIVE) Stock Down 69% Today?
investorplace.com • -
Viveve Medical, Inc. (VIVE) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Are Biotech Penny Stocks Worth Buying? Check These 3 Out
pennystocks.com • -
Viveve Announces Issuance of New Device and Methods Patent in U.S.
accesswire.com • -
Viveve Announces Adjournment of Annual Meeting
accesswire.com • -
Recap: Viveve Medical Q1 Earnings
benzinga.com • -
Viveve Announces Adjournment of Annual Meeting
accesswire.com • -
Huge Upside Potential in 5 Stocks Trading Under $10
247wallst.com • -
2 Falling Knives to Catch
gurufocus.com •